Article

What's in a name? Check out the Foundation for Women's Cancer

Author(s):

Lindsay Ray

The Gynecologic Cancer Foundation (GCF) has been doing a little spring cleaning as part of its 20th anniversary. (It was founded in 1991.) As of March 1, the foundation has a new name and is merging its four websites. All the content for the GCF, the Women's Cancer Network, the National Cervical Cancer Public Education Campaign and the National Race to End Women's Cancer will be consolidated and housed at the Foundation for Women's Cancer site. The change was made in order to help the foundation better engage supporters and professionals as well as patients, survivors and their support systems.If you're unfamiliar with these sites, they seek to promote public awareness about gynecologic cancers as well as inform women about gynecologic cancer and help them better understand the disease. Gynecologic cancers include ovarian, uterine, vaginal, vulvar, endometrial, fallopian tube, and cervical cancers.

Related Videos
Dr. Alan Tan is a genitourinary oncology (GU) and melanoma specialist at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee; an associate professor of medicine in the Division of Hematology and Oncology at Vanderbilt University Medical Center; and GU Executive Officer with the Alliance for Clinical Trials in Oncology.
Dr. Chandler Park, a medical oncologist of Genitourinary Medical Oncology, at the Norton Healthcare Institute, in Louisville, Kentucky.
Image of woman with blonde hair.
Image of woman with blonde hair.
Image of woman with brown hair.
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
a man and a woman in front of a dark blue background for CURE Speaking Out
Related Content
Illustration of bladder.
March 13th 2025

Antihistamines Associated With Bladder Cancer Survival, Progression Improvements

Alex Biese
Antihistamines are associated with improvement for patients with metastatic urothelial carcinoma receiving Tecentriq.
ROS1+ Non-Small Cell Lung Cancer: Progress in Care
September 20th 2024

ROS1+ Non-Small Cell Lung Cancer: Progress in Care

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.
Following the BCG shortage, the first patient with bladder cancer has been dosed with rBCG in the U.S. © freshidea - stock.adobe.com
March 13th 2025

First Patient Dosed With Recombinant Bacillus Calmette-Guérin in Bladder Cancer

Spencer Feldman
Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant Bacillus Calmette-Guérin in the U.S.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
It’s easy to think of scientific researchers as existing in a vacuum. © Dr_Microbe - stock.adobe.com.
March 12th 2025

Bringing Together the CAR T-Cell Therapy Community

The Leukemia & Lymphoma Society
It’s easy to think of scientific researchers as existing in a vacuum.
Nutrition is a challenge for many patients with cancer. © - stock.adobe.com
March 12th 2025

Nutrition is Key Following a Cancer Diagnosis

The Leukemia & Lymphoma Society
Nutrition is a challenge for many patients with cancer.